Schroder Investment Management Group Purchases New Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Schroder Investment Management Group bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 34,741 shares of the company’s stock, valued at approximately $949,000.

A number of other large investors have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC lifted its holdings in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the period. Avanza Fonder AB bought a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $181,000. First Bank & Trust bought a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $205,000. Moss Adams Wealth Advisors LLC purchased a new position in shares of BridgeBio Pharma in the 4th quarter valued at approximately $208,000. Finally, Legato Capital Management LLC bought a new stake in shares of BridgeBio Pharma during the fourth quarter valued at approximately $210,000. Institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Scotiabank increased their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Evercore ISI upped their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. JPMorgan Chase & Co. lifted their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.64.

BridgeBio Pharma Stock Down 2.2 %

Shares of BBIO opened at $30.67 on Tuesday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47. The company has a market capitalization of $5.83 billion, a P/E ratio of -10.76 and a beta of 1.08. The firm has a 50 day moving average of $33.89 and a 200 day moving average of $29.57.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $34.90, for a total value of $106,989,998.40. Following the transaction, the insider now directly owns 22,055,375 shares in the company, valued at $769,732,587.50. This trade represents a 12.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total value of $197,760,000.00. Following the sale, the insider now owns 19,260,971 shares of the company’s stock, valued at approximately $634,841,604.16. This trade represents a 23.75 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,684,739 shares of company stock valued at $326,958,651. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.